Table 1.
Main characteristics of all selected studies
| No | Authors (Ref) | Year (Country) | Patients | Type | Criteria | Number of Nup98 fusions | Age (year) * +/- | Sex (M/F) * +/- | WBC, *10 9 /L +/- | methods | NOS Score | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Hollink I (11) | 2011 (USA) |
1101 | AML | FAB | NUP98-NSD1+ (n: 23) |
16.8 | 40 | %65.2 / 34.8% |
%52.0/ 48% |
146.5 | 26.2 | RT-qPCR | 7 |
| 2 | ShibaN (22) | 2013 (Japan) |
124 | de novo AML | FAB | NUP98-NSD1+ (n: 24) |
8.8 | 6.7 | 14/10 | 57/43 | 74.4 | 49.7 | RT-qPCR sequencing |
7 |
| 3 | Shiba N (23) |
2015 (Japan) |
369 | de novo AML | FAB | NUP98-NSD1+ (n: 11) |
- | - | - | RT-PCR | 5 | |||
| 4 | S Struski (24) |
2016 (France) |
212 | de novo AML | FAB | NUP98-NSD1+ (n: 22) |
11.8 | 9.1 | 5/17 | 82/108 | 194 | 12.2 | RT-qPCR | 7 |
| 5 | Marceau-Renaut A (25) |
2018 (France) |
385 | de novo AML | WHO | NUP98-NSD1+ (n: 9) |
8.6 Pos: 9.9 |
210/175* | *16.6 Pos: 179.8 |
RT-qPCR | 6 | |||
| 6. | Miyamura T (26) | 2018 (Japan) |
443 | AML | FAB | NUP98-NSD1+ (n: 7) |
6.1 | - | 28/15 | - | 43 | 96 | RT-PCR | 6 |
| 7. | Niktoreh N (27) |
2019 (Germany) |
246 | de novo AML | FAB | NUP98-NSD1+/Flt3+ (n:15) |
9.09 | - | 183/170 | - | 24.5 | - | RT-qPCR | 6 |
| 8. | Ostronoff F (12) |
2014 (USA) |
253 | de novo AML | - | Nup98-NSD1+/Flt3+ (n:37) |
11 | - | 26/11 | - | 173 | - | RT-PCR sequencing |
7 |
| NUP98-NSD1+/Flt3- (n=26) |
12 | - | 19/7 | - | 79 | - | ||||||||
| 9. | Shimada Y (28) |
2017 (Japan) |
44 | de novo AML | FAB & WHO | NUP98-NSD1+/Flt3+ (n:8) |
* 10 | * 27/17 | * 71.230 | RT-PCR | 6 | |||
| 10. | Rooij JDE (29) |
2016 (USA) |
153 | AMKL | FAB | NUP98-KDM5A+ (n:14) | *1.6 Pos: 1.9 |
* 70/83 Pos: 6/8 |
*13.73 Pos: 14.03 |
RT-PCR sequencing |
6 | |||
| 11. | Rooij J (30) |
201 (Netherlands) |
93 | non-DS-AMKL | FAB | NUP98-KDM5A+ (n:10) | - | - | - | sequencing | 5 | |||
| 12. | Hara Y (31) |
2019 (Japan) |
132 | de novo AML | FAB | NUP98-KDM5A+ (n:6) | * <3 | *68/ 64 | * 30.5 | RT-PCR sequencing |
6 | |||
| 13 | Iacobucci L (32) |
2019 (Australia) |
147 | AML | FAB &WHO |
NUP98-KDM5A+ (n:7) | - | - | - | RT-PCR | 6 | |||
| 14. | Bertrums EJM (33) |
2020 (Different ethnicities) |
2396 | AML | FAB | NUP98-KDM5A+ (n:34) | 2.8 | - | 17/17 | - | 11.3 | - | sequencing | 8 |
| NUP98-NSD1+ (n: 110) |
10.0 | - | 70/40 | - | 173 | - | ||||||||
| 15. | Hara Y (34) |
2017 (Japan) |
44 | non-DS-AMKL | FAB | NUP98-KDM5A+ (n:4) | * 1 | * 21/23 | * 22.0 | RT-PCR sequencing | 6 | |||
No, Number; M, Male; F, Female; FAB, French-American-British; WHO, Word Health Organization; Ref, references; AML, Acute Megakaryoblastic Leukemia; non-DS-AMKL, acute megakaryoblastic leukemia with non-Down syndrome; qPCR, Quantitative Polymerase Chain Reaction
* Data in all patients are reported, Pos: Data is reported for patients with NUP-98 Rearrangement only.